Latest News for ORYZF
MADRID and CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the three months ended March 31, 2026, and provided a corporate update on recent developments.
MADRID and CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today announced that updated positive clinical data from two Phase Ib clinical trials evaluating its selective LSD1 inhibitor iadademstat in acute myeloid leukemia (AML) will be presented in two poster sessions at the…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for ORYZF.
Senate Trading
No Senate trades found for ORYZF.
U.S. House Trading
No House trades found for ORYZF.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.